{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:00:55Z","timestamp":1791928855545,"version":"4.3.4"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Standard treatment for human epidermal growth factor 2 positive (HER2+) breast cancer poses a high risk of cardiotoxicity, however, it still lacks predictive biomarkers. This study assesses five candidate biomarkers for early treatment-related cardiotoxicity prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>All enrolled patients received the full treatment protocol consisting of anthracycline followed by 12\u00a0months of trastuzumab alone or with pertuzumab. Patients were prospectively followed for 27\u00a0months. Measurements of high-sensitivity troponin I (hs-Tn I), high-sensitivity C reactive protein (hs-CRP), N-terminal pro b-type natriuretic peptide, interleukin-6, and uric acid were performed at baseline, after anthracyclines, and after four cycles of anti-HER2 agents. Left ventricular ejection fraction (LVEF) measurements and full cardiac examination were performed every 3\u00a0months from baseline point until study end. Cardiotoxicity was defined as either an absolute decrease in LVEF of \u226515% or a drop in LVEF of \u226510% from the baseline to &lt;50%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among 44 patients, cardiotoxicity occurred in 11 patients (25%). Higher risk of cardiotoxicity was associated with hs-Tn I levels \u226582 ng\/L measured after four cycles of anti-HER2 agents. Elevated hs-CRP values \u22652.8 mg\/L after 4 cycles of anthracyclines were also associated with increased risk. The highest risk was observed when both elevated hs-Tn I (\u226582 ng\/L after four cycles of anti-HER2 agents) and elevated hs-CRP (after four cycles of anthracyclines) were present.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The interaction between both hs-Tn I and hs-CRP demonstrates significant predictive value for cardiotoxicity risk related to HER2+\u00a0breast cancer treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000004191","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T06:00:13Z","timestamp":1761631213000},"page":"8190-8200","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A serum biomarker panel for early detection of treatment-related cardiotoxicity in early HER2-positive breast cancer patients"],"prefix":"10.1097","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3574-4275","authenticated-orcid":false,"given":"Nadeem A","family":"Ahmed","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Diseases, Faculty of Medicine, Tishreen University Hospital, Latakia, Syria"},{"name":"Cancer Research Center, Tishreen University Hospital, Latakia, Syria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem H","family":"Abbas","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tishreen University Hospital, Latakia, Syria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ward A","family":"Hasan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tishreen University Hospital, Latakia, Syria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal N","family":"Redwan","sequence":"additional","affiliation":[{"name":"Department of Laboratory and Clinical Biochemistry, Faculty of Medicine, Tishreen University Hospital, Latakia, Syria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Statistics and Programming, Faculty of Economics, Tishreen University, Latakia, Syria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-7954","authenticated-orcid":false,"given":"Zuhair A","family":"Al-Shehabi","sequence":"additional","affiliation":[{"name":"Cancer Research Center, Tishreen University Hospital, Latakia, Syria"},{"name":"Department of Pathology, Faculty of Medicine, Tishreen University Hospital, Latakia, Syria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"R1-20260319","doi-asserted-by":"crossref","first-page":"33\u201344","DOI":"10.1016\/j.breast.2020.04.005","article-title":"Cardiac monitoring in HER2-positive patients on trastuzumab treatment: a review and implications for clinical practice","volume":"52","author":"Bouwer","year":"2020","journal-title":"Breast"},{"key":"R2-20260319","doi-asserted-by":"crossref","first-page":"116\u201326","DOI":"10.1016\/j.pcad.2019.02.002","article-title":"Curing breast cancer and killing the heart: a novel model to explain elevated cardiovascular disease and mortality risk among women with early stage breast cancer","volume":"62","author":"Kirkham","year":"2019","journal-title":"Prog Cardiovasc Dis"},{"key":"R3-20260319","doi-asserted-by":"crossref","first-page":"954\u201360","DOI":"10.1161\/CIRCULATIONAHA.107.690487","article-title":"Role of neuregulin-1\/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure","volume":"116","author":"Lemmens","year":"2007","journal-title":"Circulation"},{"key":"R4-20260319","doi-asserted-by":"crossref","first-page":"1215\u201321","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"key":"R5-20260319","first-page":"100082","article-title":"Transparency in the reporting of Artificial Intelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R6-20260319","doi-asserted-by":"crossref","first-page":"1659\u201372","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"R7-20260319","doi-asserted-by":"crossref","first-page":"4229\u2013361","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"R8-20260319","doi-asserted-by":"crossref","first-page":"795\u2013804","DOI":"10.1016\/j.jchf.2019.04.014","article-title":"Decline in left ventricular ejection fraction following anthracyclines predicts trastuzumab cardiotoxicity","volume":"7","author":"Goel","year":"2019","journal-title":"JACC Heart Fail"},{"key":"R9-20260319","first-page":"CD006243","article-title":"Trastuzumab containing regimens for early breast cancer","volume":"2012","author":"Moja","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-20260319","doi-asserted-by":"crossref","first-page":"e000073","DOI":"10.1136\/esmoopen-2016-000073","article-title":"Twenty years of anti-HER2 therapy-associated cardiotoxicity","volume":"1","author":"Pond\u00e9","year":"2016","journal-title":"ESMO Open"},{"key":"R11-20260319","first-page":"93\u2013102","article-title":"Evaluating high-sensitivity cardiac troponin I for early detection of treatment-related cardiotoxicity in HER2-positive breast cancer patients","volume":"87","author":"Ahmed","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"R12-20260319","doi-asserted-by":"crossref","first-page":"133\u201346","DOI":"10.1007\/s11886-022-01834-x","article-title":"Recent advances in serum biomarkers for risk stratification and patient management in cardio-oncology","volume":"25","author":"Joolharzadeh","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"R13-20260319","first-page":"1183","article-title":"The value of troponin as a biomarker of chemotherapy-induced cardiotoxicity","volume":"12","author":"Sorodoc","year":"2022","journal-title":"Life (Basel)"},{"key":"R14-20260319","doi-asserted-by":"crossref","first-page":"1293\u2013305","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study","volume":"104","author":"Bowles","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"R15-20260319","first-page":"215\u201352","article-title":"High-sensitivity methods for cardiac troponins: the mission is not over yet","volume":"103","author":"Clerico","year":"2021","journal-title":"Adv Clin Chem"},{"key":"R16-20260319","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1515\/cclm-2019-0032","article-title":"Evaluation of reference change values for a hs-cTnI immunoassay using both plasma samples of healthy subjects and patients and quality control samples","volume":"57","author":"Musetti","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"R17-20260319","first-page":"372","article-title":"Cardiac biomarkers for the detection and management of cancer therapy-related cardiovascular toxicity","volume":"9","author":"Zhang","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"R18-20260319","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11912-020-00930-x","article-title":"Cardiac biomarkers in patients with cancer: considerations, clinical implications, and future avenues","volume":"22","author":"Bracun","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"R19-20260319","doi-asserted-by":"crossref","first-page":"34\u201343","DOI":"10.22543\/7674.81.P3443","article-title":"Biochemical and echocardiographic markers for the early detection of cardiotoxicity under monoclonal antibodies therapy","volume":"8","author":"Popovici","year":"2021","journal-title":"J Mind Med Sci"},{"key":"R20-20260319","doi-asserted-by":"crossref","first-page":"1164\u201372","DOI":"10.1373\/clinchem.2015.241232","article-title":"Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab","volume":"61","author":"Putt","year":"2015","journal-title":"Clin Chem"},{"key":"R21-20260319","doi-asserted-by":"crossref","first-page":"809\u201316","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab [published correction appears in","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R22-20260319","doi-asserted-by":"crossref","first-page":"1375\u201380","DOI":"10.1016\/j.amjcard.2011.01.006","article-title":"Early detection and prediction of cardiotoxicity in chemotherapy-treated patients","volume":"107","author":"Sawaya","year":"2011","journal-title":"Am J Cardiol"},{"key":"R23-20260319","doi-asserted-by":"crossref","first-page":"596\u2013603","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"R24-20260319","doi-asserted-by":"crossref","first-page":"126\u201337","DOI":"10.1016\/j.ejca.2018.02.005","article-title":"Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the international cardiooncology society-one trial","volume":"94","author":"Cardinale","year":"2018","journal-title":"Eur J Cancer"},{"key":"R25-20260319","doi-asserted-by":"crossref","first-page":"1663\u201368","DOI":"10.1038\/bjc.2011.439","article-title":"Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients","volume":"105","author":"Romano","year":"2011","journal-title":"Br J Cancer"},{"key":"R26-20260319","first-page":"4992\u20135001","article-title":"BNP as a marker for early prediction of anthracycline-induced cardiotoxicity in patients with breast cancer","volume":"18","author":"Lu","year":"2019","journal-title":"Oncol Lett"},{"key":"R27-20260319","doi-asserted-by":"crossref","first-page":"S4282","DOI":"10.21037\/jtd.2018.08.15","article-title":"Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity","volume":"10","author":"Michel","year":"2018","journal-title":"J Thorac Dis"},{"key":"R28-20260319","first-page":"4","article-title":"NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab","volume":"5","author":"Bouwer","year":"2019","journal-title":"Cardiooncology"},{"key":"R29-20260319","doi-asserted-by":"crossref","first-page":"475\u201381","DOI":"10.1080\/0284186X.2020.1842904","article-title":"Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumab","volume":"60","author":"Andersson","year":"2021","journal-title":"Acta Oncol"},{"key":"R30-20260319","doi-asserted-by":"crossref","first-page":"106\u201313","DOI":"10.1016\/j.breast.2020.09.001","article-title":"NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients","volume":"54","author":"Blancas","year":"2020","journal-title":"Breast"},{"key":"R31-20260319","doi-asserted-by":"crossref","first-page":"878\u201384","DOI":"10.1200\/JCO.2015.65.7916","article-title":"Role of Troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy","volume":"35","author":"Zardavas","year":"2017","journal-title":"J Clin Oncol"},{"key":"R32-20260319","doi-asserted-by":"crossref","first-page":"510\u201316","DOI":"10.1097\/COC.0000000000000699","article-title":"A prospective study about trastuzumab-induced cardiotoxicity in HER2-positive breast cancer","volume":"43","author":"Ben Kridis","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"R33-20260319","doi-asserted-by":"crossref","first-page":"76\u201383","DOI":"10.1007\/s12574-018-0394-4","article-title":"Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy","volume":"17","author":"El-Sherbeny","year":"2019","journal-title":"J Echocardiogr"},{"key":"R34-20260319","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.3390\/cancers14143353","article-title":"Biomarkers of trastuzumab-induced cardiac toxicity in HER2- positive breast cancer patient population","volume":"14","author":"Grela-Wojewoda","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R35-20260319","doi-asserted-by":"crossref","first-page":"933428","DOI":"10.3389\/fcvm.2022.933428","article-title":"Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer","volume":"9","author":"Posch","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R36-20260319","doi-asserted-by":"crossref","first-page":"631\u201338","DOI":"10.1007\/s10549-017-4628-3","article-title":"Cardiac biomarkers for early detection and prediction of trastuzumab and\/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)","volume":"168","author":"Ponde","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"R37-20260319","doi-asserted-by":"crossref","first-page":"2263\u201370","DOI":"10.1016\/j.jacc.2010.11.063","article-title":"The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy","volume":"57","author":"Fallah-Rad","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R38-20260319","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s43044-021-00142-z","article-title":"The combined role of NT-proBNP and LV-GLS in the detection of early subtle chemotherapy-induced cardiotoxicity in breast cancer female patients","volume":"73","author":"Sulaiman","year":"2021","journal-title":"Egypt Heart J"},{"key":"R39-20260319","doi-asserted-by":"crossref","first-page":"898172","DOI":"10.3389\/fsurg.2022.898172","article-title":"Early predictive value of NT-proBNP combined with echocardiography in anthracyclines induced cardiotoxicity","volume":"9","author":"Dong","year":"2022","journal-title":"Front Surg"},{"key":"R40-20260319","doi-asserted-by":"crossref","first-page":"11795549241297881","DOI":"10.1177\/11795549241297881","article-title":"Assessment of cardiotoxicity incidence in patients receiving HER-2-targeted therapies for breast cancer in Saudi Arabia","volume":"18","author":"Shahbar","year":"2024","journal-title":"Clin Med Insights Oncol"},{"key":"R41-20260319","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00395-016-0576-z","article-title":"ErbB2 signaling at the crossing between heart failure and cancer","volume":"111","author":"Vermeulen","year":"2016","journal-title":"Basic Res Cardiol"},{"key":"R42-20260319","first-page":"1\u20139","article-title":"The roles of neuregulin-1 in cardiac development, homeostasis, and disease","volume":"10","author":"Rupert","year":"2015","journal-title":"Biomark Insights"},{"key":"R43-20260319","doi-asserted-by":"crossref","first-page":"881\u201390","DOI":"10.1007\/s10741-020-10063-9","article-title":"Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets","volume":"26","author":"Fabiani","year":"2021","journal-title":"Heart Fail Rev"},{"key":"R44-20260319","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.3390\/cancers16132419","article-title":"Prevention of anthracyclines and HER2 inhibitor-induced cardiotoxicity: a systematic review and meta-analysis","volume":"16","author":"Sotiropoulou","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R45-20260319","doi-asserted-by":"crossref","first-page":"511\u201324","DOI":"10.1007\/s10557-021-07181-3","article-title":"The molecular mechanisms of cardiotoxicity induced by HER2, VEGF, and tyrosine kinase inhibitors: an updated review","volume":"36","author":"Wu","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"R46-20260319","doi-asserted-by":"crossref","first-page":"14312","DOI":"10.1038\/s41598-022-18342-1","article-title":"Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Sci Rep"},{"key":"R48-20260319","doi-asserted-by":"crossref","first-page":"971\u201377","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention","volume":"104","author":"Henriksen","year":"2018","journal-title":"Heart"},{"key":"R49-20260319","doi-asserted-by":"crossref","first-page":"291\u201398","DOI":"10.1007\/s10549-012-2039-z","article-title":"High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study","volume":"134","author":"Onitilo","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"R50-20260319","doi-asserted-by":"crossref","first-page":"1081\u201397","DOI":"10.1089\/ars.2020.8016","article-title":"Cardiac damage in anthracyclines therapy: focus on oxidative stress and inflammation","volume":"32","author":"Rocca","year":"2020","journal-title":"Antioxid Redox Signal"},{"key":"R51-20260319","doi-asserted-by":"crossref","first-page":"724\u201334","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:03:02Z","timestamp":1773936182000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004191","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"2025-06-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}